RAPT Therapeutics (RAPT) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

RAPT Stock Forecast

RAPT Therapeutics stock forecast is as follows: an average price target of $2.00 (represents a 142.31% upside from RAPT’s last price of $0.83) and a rating consensus of 'Hold', based on 7 wall street analysts offering a 1-year stock forecast.

RAPT Price Target

The average price target for RAPT Therapeutics (RAPT) is $2.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $2.00. This represents a potential 142.31% upside from RAPT's last price of $0.83.

RAPT Analyst Ratings

Hold

According to 7 Wall Street analysts, RAPT Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for RAPT stock is 0 'Strong Buy' (0.00%), 3 'Buy' (42.86%), 4 'Hold' (57.14%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

RAPT Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 12, 2024	Thomas Smith	Leerink Partners	$2.00	$1.74	14.94%	142.31%
Nov 12, 2024	Alex Thompson	Stifel Nicolaus	$2.00	$1.74	14.94%	142.31%
Jan 04, 2023		Guggenheim	$55.00	$19.82	177.43%	6563.44%
Jan 04, 2023		Wells Fargo	$48.00	$19.50	146.15%	5715.36%
Dec 08, 2022	Edward Tenthoff	Piper Sandler	$33.00	$16.48	100.24%	3898.06%
Dec 01, 2022		Goldman Sachs	$27.00	$17.68	52.71%	3171.14%
Nov 11, 2022		Piper Sandler	$34.00	$21.98	54.69%	4019.21%
Sep 21, 2022	Zegbeh Jallah	Capital One Financial	$48.00	$24.17	98.59%	5715.36%

The latest RAPT Therapeutics stock forecast, released on Nov 12, 2024 by Thomas Smith from Leerink Partners, set a price target of $2.00, which represents a 14.94% increase from the stock price at the time of the forecast ($1.74), and a 142.31% increase from RAPT last price ($0.83).

RAPT Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	2
Avg Price Target	-	$2.00	$2.00
Last Closing Price	$0.83	$0.83	$0.83
Upside/Downside	-100.00%	142.31%	142.31%

In the current month, the average price target of RAPT Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to RAPT Therapeutics's last price of $0.83. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 12, 2024	Leerink Partners	Market Perform	Market Perform	Hold
Aug 11, 2024	Wells Fargo	Overweight	Overweight	Hold
May 14, 2024	Wolfe Research		Peer Perform	Downgrade
May 10, 2024	Barclays	Overweight	Equal-Weight	Downgrade
May 09, 2024	Guggenheim	Buy	Neutral	Downgrade
May 09, 2024	Guggenheim	Buy	Hold	Downgrade
Feb 21, 2024	Cantor Fitzgerald		Neutral	Downgrade
Feb 21, 2024	Barclays	Overweight	Overweight	Hold
Feb 21, 2024	Leerink Partners		Market Perform	Downgrade
Jan 04, 2023	Guggenheim		Buy	Initialise
Jan 04, 2023	Wells Fargo	Overweight	Overweight	Hold
Dec 08, 2022	Piper Sandler	Overweight	Overweight	Hold
Dec 01, 2022	Goldman Sachs		Buy	Initialise
Nov 11, 2022	Piper Sandler	Overweight	Overweight	Hold

RAPT Therapeutics's last stock rating was published by Leerink Partners on Nov 12, 2024. The company gave RAPT a "Market Perform" rating, the same as its previous rate.

RAPT Therapeutics Financial Forecast

RAPT Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	$641.00K	-	$886.00K	$641.00K	$756.00K	$966.00K	$869.00K	$1.22M	$1.30M	$1.53M	$1.28M	$935.00K
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	$132.50K	$336.57K	$280.00K	$233.33K	$811.00K	$778.17K	$1.01M	$908.00K	$1.28M	$1.00M	$833.33K	$1.25M
High Forecast	-	-	-	-	-	-	-	-	-	-	-	$132.50K	$336.57K	$280.00K	$233.33K	$811.00K	$778.17K	$1.01M	$908.00K	$1.28M	$1.00M	$833.33K	$1.25M
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	$132.50K	$336.57K	$280.00K	$233.33K	$811.00K	$778.17K	$1.01M	$908.00K	$1.28M	$1.00M	$833.33K	$1.25M
# Analysts	-	-	-	-	-	-	-	-	-	-	-	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	4.84%	-	3.16%	2.75%	0.93%	1.24%	0.86%	1.35%	1.02%	1.53%	1.53%	0.75%

RAPT Therapeutics's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. RAPT's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $641.00K (Dec 22).

RAPT Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
# Analysts	-	-	-	-	-	-	-	-	-	-	-	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$-24.43M	$-21.42M	$-18.64M	$-20.52M	$-17.70M	$-18.42M	$-15.85M	$-16.23M	$451.26K	$-14.08M	$-11.72M	$-12.70M
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	$-26.50K	$-67.31K	$-56.00K	$-19.91M	$-162.20K	$-155.63K	$-202.50K	$-15.19M	$-255.28K	$-200.15K	$-166.67K	$-8.86M
High Forecast	-	-	-	-	-	-	-	-	-	-	-	$-26.50K	$-67.31K	$-56.00K	$-15.93M	$-162.20K	$-155.63K	$-202.50K	$-12.15M	$-255.28K	$-200.15K	$-166.67K	$-7.09M
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	$-26.50K	$-67.31K	$-56.00K	$-23.89M	$-162.20K	$-155.63K	$-202.50K	$-18.22M	$-255.28K	$-200.15K	$-166.67K	$-10.64M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	921.96%	318.18%	332.77%	1.03%	109.11%	118.37%	78.29%	1.07%	-1.77%	70.35%	70.34%	1.43%

1 analysts predict RAPT's average Quarter EBITDA for Mar 21 to be $-15.19M, with a high of $-12.15M and a low of $-18.22M. This is -3465.35% lower than RAPT Therapeutics's previous annual EBITDA (Dec 20) of $451.26K.

RAPT Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
# Analysts	-	-	-	-	-	-	-	-	-	-	-	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	$-21.47M	$-20.79M	$-19.46M	$-20.16M	$-17.93M	$-18.65M	$-16.11M	$-16.51M	$-12.73K	$-14.63M	$-12.39M	$-13.14M
Avg Forecast	$-19.55M	$-19.56M	$-18.09M	$-18.09M	$-17.77M	$-18.41M	$-18.67M	$-18.67M	$-16.21M	$-22.55M	$-28.00M	$-25.45M	$-26.08M	$-28.73M	$-20.17M	$-25.70M	$-24.20M	$-26.41M	$-15.45M	$-22.54M	$-21.84M	$-22.99M	$-9.17M
High Forecast	$-19.55M	$-19.56M	$-18.09M	$-18.09M	$-17.77M	$-18.41M	$-18.67M	$-14.28M	$-13.39M	$-22.55M	$-28.00M	$-25.45M	$-26.08M	$-28.73M	$-16.13M	$-25.70M	$-24.20M	$-26.41M	$-12.36M	$-22.54M	$-21.84M	$-22.99M	$-7.33M
Low Forecast	$-19.55M	$-19.56M	$-18.09M	$-18.09M	$-17.77M	$-18.41M	$-18.67M	$-23.07M	$-20.44M	$-22.55M	$-28.00M	$-25.45M	$-26.08M	$-28.73M	$-24.20M	$-25.70M	$-24.20M	$-26.41M	$-18.54M	$-22.54M	$-21.84M	$-22.99M	$-11.00M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.84%	0.80%	0.68%	1.00%	0.70%	0.77%	0.61%	1.07%	0.00%	0.67%	0.54%	1.43%

RAPT Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RAPT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

RAPT Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
# Analysts	-	-	-	-	-	-	-	-	-	-	-	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	$4.98M	$5.08M	$5.44M	$4.75M	$4.49M	$3.77M	$3.76M	$4.01M	$3.48M	$3.20M	$2.80M	$3.29M
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	$582.83K	$1.48M	$1.23M	$1.03M	$3.57M	$3.42M	$4.45M	$3.99M	$5.61M	$4.40M	$3.67M	$5.50M
High Forecast	-	-	-	-	-	-	-	-	-	-	-	$582.83K	$1.48M	$1.23M	$1.03M	$3.57M	$3.42M	$4.45M	$3.99M	$5.61M	$4.40M	$3.67M	$5.50M
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	$582.83K	$1.48M	$1.23M	$1.03M	$3.57M	$3.42M	$4.45M	$3.99M	$5.61M	$4.40M	$3.67M	$5.50M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	8.54%	3.43%	4.41%	4.63%	1.26%	1.10%	0.84%	1.00%	0.62%	0.73%	0.76%	0.60%

RAPT Therapeutics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to RAPT last annual SG&A of $4.98M (Dec 22).

RAPT Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
# Analysts	-	-	-	-	-	-	-	-	-	-	-	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	$-0.60	$-0.62	$-0.62	$-0.68	$-0.61	$-0.63	$-0.63	$-0.66	$-0.00	$-0.60	$-0.51	$-0.56
Avg Forecast	$-0.50	$-0.50	$-0.46	$-0.47	$-0.46	$-0.47	$-0.48	$-0.48	$-0.42	$-0.58	$-0.72	$-0.65	$-0.67	$-0.74	$-0.68	$-0.66	$-0.62	$-0.68	$-0.60	$-0.58	$-0.56	$-0.59	$-0.49
High Forecast	$-0.50	$-0.50	$-0.46	$-0.47	$-0.46	$-0.47	$-0.48	$-0.37	$-0.34	$-0.58	$-0.72	$-0.65	$-0.67	$-0.74	$-0.68	$-0.66	$-0.62	$-0.68	$-0.60	$-0.58	$-0.56	$-0.59	$-0.49
Low Forecast	$-0.50	$-0.50	$-0.46	$-0.47	$-0.46	$-0.47	$-0.48	$-0.59	$-0.53	$-0.58	$-0.72	$-0.65	$-0.67	$-0.74	$-0.68	$-0.66	$-0.62	$-0.68	$-0.60	$-0.58	$-0.56	$-0.59	$-0.49
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.92%	0.92%	0.84%	1.00%	0.92%	1.01%	0.93%	1.10%	0.00%	1.07%	0.86%	1.14%

According to undefined Wall Street analysts, RAPT Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RAPT previous annual EPS of $NaN (undefined).

RAPT Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
BDTX	Black Diamond Therapeutics	$2.50	$20.00	700.00%	Buy
XLO	Xilio Therapeutics	$0.93	$7.00	652.69%	Buy
HOWL	Werewolf Therapeutics	$1.64	$12.00	631.71%	Buy
PEPG	PepGen	$4.30	$29.50	586.05%	Buy
MOLN	Molecular Partners	$5.25	$29.00	452.38%	Buy
ANEB	Anebulo Pharmaceuticals	$1.31	$6.00	358.02%	Buy
RLAY	Relay Therapeutics	$4.50	$18.00	300.00%	Buy
PMVP	PMV Pharmaceuticals	$1.52	$6.00	294.74%	Buy
ANTX	AN2 Therapeutics	$1.34	$5.00	273.13%	Buy
ARVN	Arvinas	$19.10	$58.50	206.28%	Buy
PLRX	Pliant Therapeutics	$14.37	$35.50	147.04%	Buy
MLYS	Mineralys Therapeutics	$12.35	$30.00	142.91%	Buy
RAPT	RAPT Therapeutics	$0.84	$2.00	138.10%	Hold
PHVS	Pharvaris	$18.49	$42.00	127.15%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
TYRA	Tyra Biosciences	$15.22	$31.75	108.61%	Buy
DSGN	Design Therapeutics	$6.25	$9.67	54.72%	Buy
CNTB	Connect Biopharma	$1.06	$1.50	41.51%	Buy
IKNA	Ikena Oncology	$1.62	$1.33	-17.90%	Buy

RAPT Forecast FAQ

Is RAPT Therapeutics a good buy?

No, according to 7 Wall Street analysts, RAPT Therapeutics (RAPT) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 42.86% of RAPT's total ratings.

What is RAPT's price target?

RAPT Therapeutics (RAPT) average price target is $2 with a range of $2 to $2, implying a 142.31% from its last price of $0.825. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will RAPT Therapeutics stock go up soon?

According to Wall Street analysts' prediction for RAPT stock, the company can go up by 142.31% (from the last price of $0.825 to the average price target of $2), up by 142.31% based on the highest stock price target, and up by 142.31% based on the lowest stock price target.

Can RAPT Therapeutics stock reach $1?

RAPT's average twelve months analyst stock price target of $2 supports the claim that RAPT Therapeutics can reach $1 in the near future.

What are RAPT Therapeutics's analysts' financial forecasts?

RAPT Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-73.528M (high $-69.134M, low $-77.921M), average SG&A $0 (high $0, low $0), and average EPS is $-1.89 (high $-1.777, low $-2.003). RAPT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-75.289M (high $-75.289M, low $-75.289M), average SG&A $0 (high $0, low $0), and average EPS is $-1.935 (high $-1.935, low $-1.935).

Did the RAPT's actual financial results beat the analysts' financial forecasts?

Based on RAPT Therapeutics's last annual report (Dec 2022), the company's revenue was $1.53M, beating the average analysts forecast of $982.4K by 55.44%. Apple's EBITDA was $-85.795M, beating the average prediction of $-20.06M by 327.70%. The company's net income was $-81.881M, missing the average estimation of $-100M by -18.47%. Apple's SG&A was $20.24M, beating the average forecast of $4.32M by 368.38%. Lastly, the company's EPS was $-2.52, missing the average prediction of $-2.743 by -8.14%. In terms of the last quarterly report (Dec 2022), RAPT Therapeutics's revenue was $641K, beating the average analysts' forecast of $132.5K by 383.77%. The company's EBITDA was $-24.431M, beating the average prediction of $-26.499K by 92095.93%. RAPT Therapeutics's net income was $-21.471M, missing the average estimation of $-25.453M by -15.64%. The company's SG&A was $4.98M, beating the average forecast of $582.83K by 753.94%. Lastly, the company's EPS was $-0.6, missing the average prediction of $-0.654 by -8.29%